Catalio portfolio

Catalio has 19 portfolio companies on record at Recent Funding, with 6 investments in the last 12 months.

Website: cataliocapital.com.

Type: Crossover fund.

Portfolio on Recent Funding: 19.

Deals, last 12 months: 6.

Rounds led: 5 of 17.

Capital in their rounds: $1.77B.

Latest deal: Star Therapeutics · Oct 23, 2026.

About this page

It is a crossover fund based in New York, US, founded in 2020. It led 5 of the 17 rounds it joined. Its most recent investment on record is Star Therapeutics's $200M Series B+ round in October 2026, alongside Redmile Group, Janus Henderson Investors, OrbiMed and 6 others. By category, its portfolio leans toward Health and bio (18) and Manufacturing and industrial (3). It has co-invested with Novo Holdings, RA Capital Management and Sofinnova Partners, most often Novo Holdings (4 rounds).

About Catalio

Firm type: Crossover fund.

Headquarters: New York, US.

Founded: 2020.

Stages: Seed, Series A, Series B, Series C, Growth, Late Stage.

Sectors: AI & Machine Learning, Biotech, Deep Tech, Digital Health, Healthtech, Longevity, Medical Devices.

Leads rounds: No.

Portfolio companies: 125.

Exits: 8.

Rounds led: 0.

What Catalio invests in

Health and bio · 18 · 95%
Manufacturing and industrial · 3 · 16%
Data and analytics · 3 · 16%
Education · 2 · 11%
Foundation models and research · 2 · 11%
Consumer and social · 1 · 5%

Catalio recent investments

Company	Round	Date	Alongside
SStar Therapeutics	Series B+ · $200M	Oct 23, 2026	Redmile Group, Janus Henderson Investors (lead), OrbiMed (lead) +6
EEnveda	Series B+ · $311M · lead	Sep 23, 2026	ICONIQ
EEvvy	Series B+ · $40M · lead	Sep 15, 2026	none named
CClaris Bio	Series B+ · $118M · lead	Jul 28, 2026	Novo Holdings, Adage Capital Management, Janus Henderson Investors +5
AAdvanCell	Series B+ · $315M	Jul 15, 2026	Fidelity Management & Research Company, Morningside, Eli Lilly +15
SSomethings	Series A · $19.2M · lead	Feb 10, 2026	General Catalyst, Tusk Venture Partners
SSidera Bio	Series A · $109.99M	Nov 4, 2025	Gilde Healthcare, Forbion Capital Partners, Novo Holdings +1
CCartography Biosciences	Series B+ · $67M	Oct 2, 2025	Global BioAccess Fund, Wing VC, ARTIS Ventures +6

How Catalio invests

Stage	Deals	Capital in rounds
Series B+	9 53%	$1.36B
Series A	8 47%	$410.19M

Year	Deals	Capital in rounds
2021	2 12%	$130M
2022	3 18%	$94M
2024	2 12%	$142M
2025	4 24%	$399.99M
2026	6 35%	$1B

Catalio portfolio companies

SStar Therapeutics$200MSeries B+ · Oct 2026
EEnveda$311MSeries B+ · Sep 2026
EEvvy$40MSeries B+ · Sep 2026
CClaris Bio$118MSeries B+ · Jul 2026
AAdvanCell$315MSeries B+ · Jul 2026
SSomethings$19.2MSeries A · Feb 2026
SSidera Bio$109.99MSeries A · Nov 2025
CCartography Biosciences$67MSeries B+ · Oct 2025
GGlycoEra$130MSeries B+ · May 2025
CCharacter Bio$93MSeries B+ · Mar 2025
LLassen Therapeutics$85MSeries B+ · Jan 2024
XXilis$19MSeries A · Jul 2022
IImmunai$60MSeries A · Feb 2021
OOpenEvidencebacker
HHippocratic AIbacker
PPersonal Genome Diagnosticsbacker
Nnoetik_aibacker
OOctant Biobacker
LLeo Cancer Carebacker

Company	Round with Catalio	Total raised	Latest raise
SStar Therapeutics Health and bio	Oct 23, 2026 Series B+ · $200M	$415M	Oct 23, 2026 Series B+
EEnveda Health and bio	Sep 23, 2026 Series B+ · $311M · lead	$714M	Sep 23, 2026 Series B+
EEvvy Health and bio	Sep 15, 2026 Series B+ · $40M · lead	$59M	Sep 15, 2026 Series B+
CClaris Bio Health and bio	Jul 28, 2026 Series B+ · $118M · lead	$175M	Jul 28, 2026 Series B+
AAdvanCell Health and bio	Jul 15, 2026 Series B+ · $315M	$439.5M	Jul 15, 2026 Series B+
SSomethings Health and bio	Feb 10, 2026 Series A · $19.2M · lead	$22.4M	Feb 10, 2026 Series A
SSidera Bio Health and bio	Nov 4, 2025 Series A · $109.99M	$109.99M	Nov 4, 2025 Series A
CCartography Biosciences Health and bio	Oct 2, 2025 Series B+ · $67M	$124M	Oct 2, 2025 Series B+
GGlycoEra Health and bio	May 27, 2025 Series B+ · $130M	$179M	May 27, 2025 Series B+
CCharacter Bio Health and bio	Mar 25, 2025 Series B+ · $93M	$111M	Mar 25, 2025 Series B+
LLassen Therapeutics Health and bio	Jan 17, 2024 Series B+ · $85M	$116M	Jan 17, 2024 Series B+
XXilis Health and bio	Jul 1, 2022 Series A · $19M	$92M	Sep 16, 2022 Series A
IImmunai Health and bio	Feb 1, 2021 Series A · $60M · lead	$295M	Oct 28, 2021 Series B+
OOpenEvidence Foundation models and research	backer	$985M	Sep 24, 2026 Series B+
HHippocratic AI Foundation models and research	backer	$385M	Nov 3, 2025 Series B+
PPersonal Genome Diagnostics Health and bio	backer	$123.8M	Nov 24, 2025 Series B+
Nnoetik_ai	backer	$14M	Jul 21, 2026 round
OOctant Bio Health and bio	backer	$115M	Oct 23, 2025 Series B+
LLeo Cancer Care Health and bio	backer	$105M	Jul 8, 2026 Series B+

Most frequent co-investors

Similar investors

Investors whose portfolios on Recent Funding center on the same category (Health and bio).

How this is counted

Firm profile: Fundraising Fox Open Dataset v2026-11, CC BY 4.0. Track-record counts are theirs, not Recent Funding's.

Share is of the 17 rounds on Recent Funding that name Catalio. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.

Portfolio companies are the companies on Recent Funding with a round that lists Catalio, which is a subset of its real portfolio. API: /api/v1/investors/catalio (get a free API key). More: the most active VC firms and new venture capital funds.